[go: up one dir, main page]

GB0906971D0 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation

Info

Publication number
GB0906971D0
GB0906971D0 GBGB0906971.7A GB0906971A GB0906971D0 GB 0906971 D0 GB0906971 D0 GB 0906971D0 GB 0906971 A GB0906971 A GB 0906971A GB 0906971 D0 GB0906971 D0 GB 0906971D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB0906971.7A
Other versions
GB2469791B (en
GB2469791A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LondonPharma Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB0906971.7A priority Critical patent/GB2469791B/en
Publication of GB0906971D0 publication Critical patent/GB0906971D0/en
Priority to EP10715337A priority patent/EP2424523B1/en
Priority to BRPI1014887A priority patent/BRPI1014887A8/en
Priority to JP2012506584A priority patent/JP5795760B2/en
Priority to US13/265,518 priority patent/US20120157518A1/en
Priority to CA2756925A priority patent/CA2756925A1/en
Priority to PCT/GB2010/050672 priority patent/WO2010122356A1/en
Priority to SI201030076T priority patent/SI2424523T1/en
Priority to RU2011139637/15A priority patent/RU2501550C2/en
Priority to MYPI2011005080A priority patent/MY155646A/en
Priority to PT10715337T priority patent/PT2424523E/en
Priority to HK12104912.3A priority patent/HK1164140B/en
Priority to ES10715337T priority patent/ES2390046T3/en
Priority to CN201080017965.1A priority patent/CN102395362B/en
Priority to HRP20120711AT priority patent/HRP20120711T1/en
Priority to NZ595469A priority patent/NZ595469A/en
Priority to MX2011010961A priority patent/MX2011010961A/en
Priority to SG2011073954A priority patent/SG175162A1/en
Priority to MEP-2012-393A priority patent/ME02008B/en
Priority to PL10715337T priority patent/PL2424523T3/en
Priority to AU2010240654A priority patent/AU2010240654C1/en
Priority to DK10715337.1T priority patent/DK2424523T3/en
Priority to RS20120393A priority patent/RS52430B/en
Publication of GB2469791A publication Critical patent/GB2469791A/en
Priority to ZA2011/07088A priority patent/ZA201107088B/en
Priority to IL215453A priority patent/IL215453A/en
Application granted granted Critical
Publication of GB2469791B publication Critical patent/GB2469791B/en
Priority to US14/813,424 priority patent/US20160022629A1/en
Priority to US15/697,240 priority patent/US20170368023A1/en
Priority to US16/164,610 priority patent/US20190142737A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0906971.7A 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease Expired - Fee Related GB2469791B (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GB0906971.7A GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
HRP20120711AT HRP20120711T1 (en) 2009-04-23 2010-04-23 SUBLINGUAL FORMULATION OF THE DIHIDROARTEMESININ SPRAY CONTAINING
NZ595469A NZ595469A (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
JP2012506584A JP5795760B2 (en) 2009-04-23 2010-04-23 Sublingual spray formulation containing dihydroartemisinin
US13/265,518 US20120157518A1 (en) 2009-04-23 2010-04-23 Sublingual Spray Formulation Comprising Dihydroartemesinin
CA2756925A CA2756925A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PCT/GB2010/050672 WO2010122356A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
SI201030076T SI2424523T1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
RU2011139637/15A RU2501550C2 (en) 2009-04-23 2010-04-23 Sublingual spray composition containing dihydroartemisinin
SG2011073954A SG175162A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PT10715337T PT2424523E (en) 2009-04-23 2010-04-23 SUBLINGUAL SPRAY FORMULATION UNDERSTANDING DIHIDROARTEMESININ
HK12104912.3A HK1164140B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
ES10715337T ES2390046T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
CN201080017965.1A CN102395362B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
EP10715337A EP2424523B1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
MX2011010961A MX2011010961A (en) 2009-04-23 2010-04-23 FORMULA IN SUBLINGUAL ASPERSION THAT INCLUDES DIHYDROARTEMESININE.
MEP-2012-393A ME02008B (en) 2009-04-23 2010-04-23 SUBLINGVAL FORMULATION OF DIHIDROARTEMEZININE CONTAINING SPRAY
MYPI2011005080A MY155646A (en) 2009-04-23 2010-04-23 Pharmaceutical preparation
BRPI1014887A BRPI1014887A8 (en) 2009-04-23 2010-04-23 pharmaceutical composition for use in treating neoplasms and use of a compound providing dihydroartemesinin via sublingual, transmucosal, buccal or nasal dosage
PL10715337T PL2424523T3 (en) 2009-04-23 2010-04-23 Sublingual aerosol preparation containing dihydroartemisinin
AU2010240654A AU2010240654C1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
DK10715337.1T DK2424523T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation with dihydroartemisinin
RS20120393A RS52430B (en) 2009-04-23 2010-04-23 SUBLINGVAL FORMULATION OF DIHIDROARTEMEZININE CONTAINING SPRAY
ZA2011/07088A ZA201107088B (en) 2009-04-23 2011-09-28 Sublingual spray formulation comprising dihydroartemesinin
IL215453A IL215453A (en) 2009-04-23 2011-10-02 Sublingual spray formulation comprising dihydroartemesinin
US14/813,424 US20160022629A1 (en) 2009-04-23 2015-07-30 Sublingual Spray Formulation Comprising Dihydroartemesinin
US15/697,240 US20170368023A1 (en) 2009-04-23 2017-09-06 Sublingual spray formulation comprising dihydroartemesinin
US16/164,610 US20190142737A1 (en) 2009-04-23 2018-10-18 Sublingual spray formulation comprising dihydroartemesinin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0906971.7A GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease

Publications (3)

Publication Number Publication Date
GB0906971D0 true GB0906971D0 (en) 2009-06-03
GB2469791A GB2469791A (en) 2010-11-03
GB2469791B GB2469791B (en) 2011-12-14

Family

ID=40774834

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0906971.7A Expired - Fee Related GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease

Country Status (1)

Country Link
GB (1) GB2469791B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
CH692321A5 (en) * 1997-11-03 2002-05-15 Mepha Ag Pharmaceutically effective composition which comprises an effective anti-malarial parasite substance.
CN1084333C (en) * 1998-06-17 2002-05-08 中国科学院上海药物研究所 Artemisine compounds, their preparing process and medicine composition containing them
EP1531851B1 (en) * 2002-06-06 2011-12-14 University of Washington Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
ATE544444T1 (en) * 2005-10-11 2012-02-15 Yissum Res Dev Co COMPOSITIONS FOR NASAL DELIVERY
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition

Also Published As

Publication number Publication date
GB2469791B (en) 2011-12-14
GB2469791A (en) 2010-11-03

Similar Documents

Publication Publication Date Title
ZA201107776B (en) Pharmaceutical composition
ZA201200719B (en) Pharmaceutical formulation
SG2014014807A (en) Pharmaceutical compositions
EP2379077A4 (en) Pharmaceutical composition
ZA201104348B (en) Pharmaceutical preparation
IL215962A0 (en) Soilid preparation
GB0815972D0 (en) Pharmaceutical preparation
GB0922589D0 (en) Pharmaceutical compounds
IL219018A0 (en) Pharmaceutical compositions
GB0908905D0 (en) Pharmaceutical compounds
GB0922537D0 (en) Pharmaceutical preparation
GB0919650D0 (en) Pharmaceutical composition
GB201115179D0 (en) Pharmaceutical preparation
GB201115173D0 (en) Pharmaceutical preparation
GB0906971D0 (en) Pharmaceutical preparation
GB0910772D0 (en) Pharmaceutical
PL390620A1 (en) Pharmaceutical preparation
GB0922523D0 (en) Pharmaceutical compounds
GB0917677D0 (en) Pharmaceutical compounds
GB0916458D0 (en) Pharmaceutical compounds
GB0915678D0 (en) Pharmaceutical compounds
GB0915125D0 (en) Pharmaceutical compounds
GB0911699D0 (en) Pharmaceutical compounds
GB0910240D0 (en) Odontalgic preparation
HU0900010D0 (en) Improved pharmaceutical composition

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: LONDONPHARMA LIMITED

Free format text: FORMER OWNER: CALVIN JOHN ROSS

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20210423

S28 Restoration of ceased patents (sect. 28/pat. act 1977)

Free format text: APPLICATION FILED

S28 Restoration of ceased patents (sect. 28/pat. act 1977)

Free format text: RESTORATION ALLOWED

Effective date: 20220511

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20230423